Literature DB >> 30022550

Assessing high-intensity focused ultrasound treatment of prostate cancer with hyperpolarized 13 C dual-agent imaging of metabolism and perfusion.

Jessie E Lee1,2, Chris J Diederich1,2,3, Robert Bok1, Renuka Sriram1, Romelyn Delos Santos1, Susan M Noworolski1,2, Vasant A Salgaonkar3, Matthew S Adams2,3, Daniel B Vigneron1,2, John Kurhanewicz1,2.   

Abstract

The goal of the study was to establish early hyperpolarized (HP) 13 C MRI metabolic and perfusion changes that predict effective high-intensity focused ultrasound (HIFU) ablation and lead to improved adjuvant treatment of partially treated regions. To accomplish this a combined HP dual-agent (13 C pyruvate and 13 C urea) 13 C MRI/multiparametric 1 H MRI approach was used to measure prostate cancer metabolism and perfusion 3-4 h, 1 d, and 5 d after exposure to ablative and sub-lethal doses of HIFU within adenocarcinoma of mouse prostate tumors using a focused ultrasound applicator designed for murine studies. Pathologic and immunohistochemical analysis of the ablated tumor demonstrated fragmented, non-viable cells and vasculature consistent with coagulative necrosis, and a mixture of destroyed tissue and highly proliferative, poorly differentiated tumor cells in tumor tissues exposed to sub-lethal heat doses in the ablative margin. In ablated regions, the intensity of HP 13 C lactate or HP 13 C urea and dynamic contrast-enhanced (DCE) MRI area under the curve images were reduced to the level of background noise by 3-4 h after treatment with no recovery by the 5 d time point in either case. In the tissues that received sub-lethal heat dose, there was a significant 60% ± 12.4% drop in HP 13 C lactate production and a significant 30 ± 13.7% drop in urea perfusion 3-4 h after treatment, followed by recovery to baseline by 5 d after treatment. DCE MRI Ktrans showed a similar trend to HP 13 C urea, demonstrating a complete loss of perfusion with no recovery in the ablated region, while having a 40%-50% decrease 3-4 h after treatment followed by recovery to baseline values by 5 d in the margin region. The utility of the HP 13 C MR measures of perfusion and metabolism in optimizing focal HIFU, either alone or in combination with adjuvant therapy, deserves further testing in future studies.
© 2018 John Wiley & Sons, Ltd.

Entities:  

Keywords:  HIFU; hyperpolarized 13C MRI; prostate cancer; pyruvate metabolism; urea perfusion

Mesh:

Substances:

Year:  2018        PMID: 30022550      PMCID: PMC6338537          DOI: 10.1002/nbm.3962

Source DB:  PubMed          Journal:  NMR Biomed        ISSN: 0952-3480            Impact factor:   4.044


  64 in total

1.  3D Slicer as an image computing platform for the Quantitative Imaging Network.

Authors:  Andriy Fedorov; Reinhard Beichel; Jayashree Kalpathy-Cramer; Julien Finet; Jean-Christophe Fillion-Robin; Sonia Pujol; Christian Bauer; Dominique Jennings; Fiona Fennessy; Milan Sonka; John Buatti; Stephen Aylward; James V Miller; Steve Pieper; Ron Kikinis
Journal:  Magn Reson Imaging       Date:  2012-07-06       Impact factor: 2.546

Review 2.  New advances in focal therapy for early stage prostate cancer.

Authors:  Kae Jack Tay; Ariel A Schulman; Christina Sze; Efrat Tsivian; Thomas J Polascik
Journal:  Expert Rev Anticancer Ther       Date:  2017-06-28       Impact factor: 4.512

3.  Assessing Prostate Cancer Aggressiveness with Hyperpolarized Dual-Agent 3D Dynamic Imaging of Metabolism and Perfusion.

Authors:  Hsin-Yu Chen; Peder E Z Larson; Robert A Bok; Cornelius von Morze; Renuka Sriram; Romelyn Delos Santos; Justin Delos Santos; Jeremy W Gordon; Naeim Bahrami; Marcus Ferrone; John Kurhanewicz; Daniel B Vigneron
Journal:  Cancer Res       Date:  2017-04-20       Impact factor: 12.701

4.  Real-time magnetic resonance-guided high-intensity focused ultrasound focal therapy for localised prostate cancer: preliminary experience.

Authors:  Alessandro Napoli; Michele Anzidei; Cosimo De Nunzio; Gaia Cartocci; Valeria Panebianco; Carlo De Dominicis; Carlo Catalano; Federico Petrucci; Costantino Leonardo
Journal:  Eur Urol       Date:  2012-11-12       Impact factor: 20.096

5.  Imaging of blood flow using hyperpolarized [(13)C]urea in preclinical cancer models.

Authors:  Cornelius von Morze; Peder E Z Larson; Simon Hu; Kayvan Keshari; David M Wilson; Jan Henrik Ardenkjaer-Larsen; Andrei Goga; Robert Bok; John Kurhanewicz; Daniel B Vigneron
Journal:  J Magn Reson Imaging       Date:  2011-03       Impact factor: 4.813

6.  Temperature relationships of proton spin-lattice relaxation time T1 in biological tissues.

Authors:  C J Lewa; Z Majewska
Journal:  Bull Cancer       Date:  1980       Impact factor: 1.276

Review 7.  Magnetic resonance imaging of the tumor microenvironment in radiotherapy: perfusion, hypoxia, and metabolism.

Authors:  Masayuki Matsuo; Shingo Matsumoto; James B Mitchell; Murali C Krishna; Kevin Camphausen
Journal:  Semin Radiat Oncol       Date:  2014-07       Impact factor: 5.934

8.  Detecting tumor response to treatment using hyperpolarized 13C magnetic resonance imaging and spectroscopy.

Authors:  Sam E Day; Mikko I Kettunen; Ferdia A Gallagher; De-En Hu; Mathilde Lerche; Jan Wolber; Klaes Golman; Jan Henrik Ardenkjaer-Larsen; Kevin M Brindle
Journal:  Nat Med       Date:  2007-10-28       Impact factor: 53.440

9.  Hyperpolarized 1-[13C]-Pyruvate Magnetic Resonance Imaging Detects an Early Metabolic Response to Androgen Ablation Therapy in Prostate Cancer.

Authors:  Rahul Aggarwal; Daniel B Vigneron; John Kurhanewicz
Journal:  Eur Urol       Date:  2017-07-29       Impact factor: 20.096

10.  The magnetic susceptibility effect of gadolinium-based contrast agents on PRFS-based MR thermometry during thermal interventions.

Authors:  Nicole M Hijnen; Aaldert Elevelt; Jeroen Pikkemaat; Clemens Bos; Lambertus W Bartels; Holger Grüll
Journal:  J Ther Ultrasound       Date:  2013-06-04
View more
  6 in total

Review 1.  Hyperpolarized 13C MRI: State of the Art and Future Directions.

Authors:  Zhen J Wang; Michael A Ohliger; Peder E Z Larson; Jeremy W Gordon; Robert A Bok; James Slater; Javier E Villanueva-Meyer; Christopher P Hess; John Kurhanewicz; Daniel B Vigneron
Journal:  Radiology       Date:  2019-03-05       Impact factor: 11.105

2.  Simultaneous Metabolic and Perfusion Imaging Using Hyperpolarized 13C MRI Can Evaluate Early and Dose-Dependent Response to Radiation Therapy in a Prostate Cancer Mouse Model.

Authors:  Hecong Qin; Vickie Zhang; Robert A Bok; Romelyn Delos Santos; J Adam Cunha; I-Chow Hsu; Justin Delos Santos Bs; Jessie E Lee; Subramaniam Sukumar; Peder E Z Larson; Daniel B Vigneron; David M Wilson; Renuka Sriram; John Kurhanewicz
Journal:  Int J Radiat Oncol Biol Phys       Date:  2020-04-25       Impact factor: 7.038

3.  Simulation-based design and characterization of a microwave applicator for MR-guided hyperthermia experimental studies in small animals.

Authors:  Pegah Faridi; Stefan H Bossmann; Punit Prakash
Journal:  Biomed Phys Eng Express       Date:  2019-11-27

Review 4.  Assessing Therapeutic Efficacy in Real-time by Hyperpolarized Magnetic Resonance Metabolic Imaging.

Authors:  Prasanta Dutta; Travis C Salzillo; Shivanand Pudakalakatti; Seth T Gammon; Benny A Kaipparettu; Florencia McAllister; Shawn Wagner; Daniel E Frigo; Christopher J Logothetis; Niki M Zacharias; Pratip K Bhattacharya
Journal:  Cells       Date:  2019-04-11       Impact factor: 6.600

5.  A Review of Imaging Methods to Assess Ultrasound-Mediated Ablation.

Authors:  Brett Z Fite; James Wang; Pejman Ghanouni; Katherine W Ferrara
Journal:  BME Front       Date:  2022-05-02

6.  Clinical translation of hyperpolarized 13 C pyruvate and urea MRI for simultaneous metabolic and perfusion imaging.

Authors:  Hecong Qin; Shuyu Tang; Andrew M Riselli; Robert A Bok; Romelyn Delos Santos; Mark van Criekinge; Jeremy W Gordon; Rahul Aggarwal; Rui Chen; Gregory Goddard; Chunxin Tracy Zhang; Albert Chen; Galen Reed; Daniel M Ruscitto; James Slater; Renuka Sriram; Peder E Z Larson; Daniel B Vigneron; John Kurhanewicz
Journal:  Magn Reson Med       Date:  2021-08-10       Impact factor: 3.737

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.